Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lidia Perea

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Scientific Reports|July 1, 2026
Clinical impact of mucus plugs in bronchiectasisAlessandro De Angelis, Lidia Perea, Pau Marrades, et al.
American Journal of Respiratory and Critical Care Medicine|September 28, 2023
Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort StudyHayoung Choi, Soorack Ryu, Holly R Keir, et al.
Ebiomedicine|January 3, 2026
Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary diseaseJulieta Viglino, Lidia Perea, Marian Garcia-Nuñez, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Characterization of Eosinophilic Bronchiectasis: A European Multicohort StudyAmelia Shoemark, Michal Shteinberg, Anthony De Soyza, et al.
The European Respiratory Journal|May 29, 2024
Airway IL-1β is related to disease severity and mucociliary function in bronchiectasisLidia Perea, Mathieu Bottier, Erin Cant, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2024
Endotypes of Exacerbation in Bronchiectasis: An Observational Cohort StudyYonghua Gao, Hollian Richardson, Alison J Dicker, et al.
The Lancet. Respiratory Medicine|February 20, 2021
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort studyHolly R Keir, Amelia Shoemark, Alison J Dicker, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
American Journal of Respiratory and Critical Care Medicine|June 25, 2026
The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registryOriol Sibila, Lidia Perea, Pierre Regis Burgel, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Scientific Reports|July 1, 2026
Clinical impact of mucus plugs in bronchiectasisAlessandro De Angelis, Lidia Perea, Pau Marrades, et al.
American Journal of Respiratory and Critical Care Medicine|September 28, 2023
Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort StudyHayoung Choi, Soorack Ryu, Holly R Keir, et al.
Ebiomedicine|January 3, 2026
Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary diseaseJulieta Viglino, Lidia Perea, Marian Garcia-Nuñez, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Characterization of Eosinophilic Bronchiectasis: A European Multicohort StudyAmelia Shoemark, Michal Shteinberg, Anthony De Soyza, et al.
The European Respiratory Journal|May 29, 2024
Airway IL-1β is related to disease severity and mucociliary function in bronchiectasisLidia Perea, Mathieu Bottier, Erin Cant, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2024
Endotypes of Exacerbation in Bronchiectasis: An Observational Cohort StudyYonghua Gao, Hollian Richardson, Alison J Dicker, et al.
The Lancet. Respiratory Medicine|February 20, 2021
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort studyHolly R Keir, Amelia Shoemark, Alison J Dicker, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
American Journal of Respiratory and Critical Care Medicine|June 25, 2026
The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registryOriol Sibila, Lidia Perea, Pierre Regis Burgel, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
Pageof 5